NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy

Tanvir Kabir, M, Sufian, MA, Sahab Uddin, M, Marium Begum, M, Akhter, S, Islam, Ariful, Mathew, B, Siddiqul Islam, M, Shah Amran, M and Ashraf, GM 2019, NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy, Current Pharmaceutical Design, vol. 25, no. 33, pp. 3506-3518, doi: 10.2174/1381612825666191011102444.

Title NMDA receptor antagonists: Repositioning of memantine as a multitargeting agent for Alzheimer's therapy
Author(s) Tanvir Kabir, M
Sufian, MA
Sahab Uddin, M
Marium Begum, M
Akhter, S
Islam, ArifulORCID iD for Islam, Ariful orcid.org/0000-0002-9210-3351
Mathew, B
Siddiqul Islam, M
Shah Amran, M
Ashraf, GM
Journal name Current Pharmaceutical Design
Volume number 25
Issue number 33
Start page 3506
End page 3518
Total pages 12
Publisher Bentham Science Publishers
Place of publication Schiphol, The Netherlands
Publication date 2019-11-19
ISSN 1381-6128
Keyword(s) NMDA antagonists
glutamate receptors
amyloid beta
Alzheimer’s disease
Summary Alzheimer’s disease (AD) is a progressive neurodegenerative disease that causes problems with memory,thinking, and behavior. Currently, there is no drug that can reduce the pathological events of this degenerativedisease but symptomatic relief is possible that can abate the disease condition. N-methyl-D-aspartate(NMDA) receptors exert a critical role for synaptic plasticity as well as transmission. Overstimulation of glutamatereceptors, predominantly NMDA type, may cause excitotoxic effects on neurons and is recommended as amechanism for neurodegeneration. Atypical activation of the NMDA receptor has been suggested for AD bysynaptic dysfunction. NMDA receptor antagonists especially memantine block the NMDA receptor and can reducethe influx of calcium (Ca2+) ions into neuron, thus, toxic intracellular events are not activated. This reviewrepresents the role of NMDA receptors antagonists as potential therapeutic agents to reduce AD. Moreover, thisreview highlights the repositioning of memantine as a potential novel therapeutic multitargeting agent for AD.
Language eng
DOI 10.2174/1381612825666191011102444
Indigenous content off
Field of Research 1115 Pharmacology and Pharmaceutical Sciences
HERDC Research category C1.1 Refereed article in a scholarly journal
Persistent URL http://hdl.handle.net/10536/DRO/DU:30150462

Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 0 times in TR Web of Science
Scopus Citation Count Cited 42 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 10 Abstract Views  -  Detailed Statistics
Created: Fri, 30 Apr 2021, 08:12:28 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.